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Introduction
There is overwhelming evidence from a number of 
uncontrolled series that patients receiving treat-
ment with immune checkpoint inhibitors (ICPIs) 
for advanced malignancies including metastatic 
cancer, especially melanoma, are at risk for devel-
oping immune-related neurological events that 
predominantly affect the neuromuscular system.1–7 
This seems like a ‘double vulnerability’ of the nerv-
ous system in cancer patients because, in addition 
to a potential paraneoplastic effect exerted by the 
cancer itself and the neurotoxicity of some chemo-
therapeutic agents, cancer immunotherapies can 
unleash unrestrained T cells capable of triggering 
autoimmune neurological diseases. Other organs, 
such as liver, skin, endocrine and rheumatic tissues 
can also be affected.1,8–10
The phenomenon is a sophisticated double immu-
notherapeutic twist: agents against the ‘inhibitory’ 
co-stimulatory T cell molecules activate T cells to 
kill the tumor but become unleashed and so ‘unin-
hibited’ that they also attack healthy tissues, caus-
ing autoimmune diseases; in turn, immunotherapy 
is needed again to reverse the T cell-triggered auto-
immunity. The purpose of this review is to high-
light the neurological complications associated with 
ICPIs; increase the awareness of the neurologists to 
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Abstract: Patients with advanced malignancies treated with immune checkpoint inhibitors 
are at increased risk for developing immune-related neurological complications. It is a 
phenomenon of immunological twist when immunotherapy against co-stimulatory molecules 
activates previously normal T cells to kill tumor cells but, in so doing, the T cells become 
unrestrained, triggering other autoimmune diseases for which conventional immunotherapy 
is needed. The most common autoimmune neurological diseases, usually occurring within 
2–12 weeks after immune checkpoint inhibitor initiation, include: inflammatory myopathies, 
myasthenia gravis, acute and chronic demyelinating polyradiculoneuropathies, vasculitic 
neuropathies, isolated cranial neuropathies, aseptic meningitis, autoimmune encephalitis, 
multiple sclerosis and hypophysitis. The neurological events can evolve rapidly, necessitating 
the need for vigilance at all stages of treatment, even after completion, because early 
immunotherapeutic interventions are effective. The review addresses these complications 
and the applied therapies, discusses immune pathomechanisms including triggering 
preexisting autoimmunity, highlights the distinction between paraneoplastic and autoimmune 
etiologies, and identifies uncertainties regarding risk factors, use of immune checkpoint 
inhibitors in patients with known immune diseases or restarting therapy after a neurological 
event. Although the autoimmune neurological complications are not very common, their 
incidence will likely increase as the use of immune checkpoint inhibitors in metastatic cancer 
is growing rapidly.
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identify them promptly because if treated early 
they can be reversed; address immunopathogene-
sis; discuss therapies; and pinpoint a series of 
evolving uncertainties regarding risk factors and 
the decision to administer ICPIs in a setting of an 
active or preexisting autoimmune neurological 
disease.
Immune tolerance, disturbance of immune 
balance by ICPIs and immunopathogenesis of 
ICPI-triggered autoimmunity
The interaction of T cell receptor (TCR) with the 
target antigen presenting cell (APC)/MHC com-
plex leads to engagement of the co-stimulatory 
factors CD28, CTLA-4 and PD-1 on T cells, 
with their respective receptors CD80 (B7-1)/
CD86(B7-2) and PD-LI-1/PDL-2 on APCs 
(Figure 1(a)).11–13 This process activates down-
stream events leading via the IL-2 promoter to cell 
proliferation and T cell differentiation.11,12 As 
shown in Figure 1(a), when CD28 binds to its 
CD80(B71)/CD86(B7-2) receptor, it exerts posi-
tive (+) activating signals; in contrast, the CTLA-4 
on activated T cells binds with higher affinity to 
CD80/CD86, exerting negative (−) inhibitory sig-
nals and blocking T cell activation. In autoimmune 
diseases the concept of target-specific immuno-
therapies is based on therapeutic monoclonal anti-
bodies or fusion proteins directed against the 
activating positive CD28 and CD80/86 (B7-1,2) 
signals,8–13 or in enhancing inhibition, like the 
CTLA-4 Ig fusion protein (Abatacept) (Figure 1(a)) 
that is effective in rheumatoid arthritis.8,9
Tumors, like other APCs, also express on their 
cell surface the inhibitory ligands PD-L1/PDL-2 
and B7-1/B7-2, which are respectively engaged 
with PD-1 and CTLA-4 on T cells, downregulat-
ing T cell responses (Figure 1(a)). These recep-
tor–ligand interactions essentially act as an ‘off 
switch’, which ‘tell the T cells to leave the tumor 
cells alone’ so T cells do not attack the tumor. As 
shown in Figure 1(b), the ICPIs prevent the 
CTLA-4 or PD-1 from binding to their respective 
receptors CD80/86 and PDL-1 and, by doing so, 
inhibit the inherent ‘inhibitory’ co-stimulatory 
interactions between T cells and tumor cells, 
resulting in positive (+) signals; ICPIs essentially 
turn the ‘switch’ back on, resulting in positive co-
stimulation and strong cell activation, like taking 
the ‘brakes off’ the immune system (Figure 1(b)).1,7–
13 Although this blockade has a positive (thera-
peutic) effect because the T cells are now able to 
kill tumor cells, it concurrently has an opposite 
negative effect as the resulting enhanced co-stim-
ulation causes an uncontrolled T cell activation 
that disrupts immune tolerance, resulting in 
immune-related events against various organs.
The exact pathomechanisms by which these 
blocked interactions lead to diversity of autoim-
mune complications remain unclear. ICPIs 
enhance Th1 and Th-17 cell responses and the 
production of cytokines, such as IL-6 and IL-17 
that lead to abnormal T-regulatory (Treg) cell 
function and humoral immunity (Figure 1(b)).2,13,14 
An altered Treg/Th17 cell axis is critical for the 
development of many autoimmune diseases. 
Further, both PD-1 and CTLA-4 inhibitions can 
stimulate antibody production, leading to anti-
body-mediated autoimmune diseases, especially in 
patients with preexisting autoimmunity or autoim-
mune susceptibility (Figure 1(b)). The patho-
genicity of some autoantibodies is facilitated by 
molecular mimicry due to cross-reactivity of cer-
tain nervous system antigens with the same anti-
gens expressed by the tumor, especially melanoma, 
as discussed later.
Commonly used ICPIs
ICPIs are currently FDA-approved for advanced 
malignancies, especially metastatic melanoma, 
non-small cell lung cancer (NSCLC) and 
Hodgkin’s lymphoma (HL).1 A complete list of 
ICPIs, indicated for each specific malignancy 
type as approved by the FDA, has been recently 
published.1 The main drugs currently on the mar-
ket are directed against the following:
(1) CTLA-4: Ipilimumab (Yervoy), the first 
ICPI approved for metastatic melanoma.
(2) PD-1: Pembrolizumab (Keytruda) and 
Nivolumab (Opdivo), with a 26–31% 
response rate among patients with meta-
static melanoma refractory to ipilimumab. 
These are also approved for a subset of 
patients with NSCLC, metastatic head and 
neck cancer, renal cell carcinoma and HL.
(3) PD-L1: Atezolizumab (Tecentriq), Avelu-
mab (Bavencio) and Durvalumab (Imfinzi), 
all approved for urothelial carcinoma and as 
second-line therapy for NSCLC.
Some of these agents are also used in combina-
tion with even better response rates, but more 
common immune complications. For example, a 
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Figure 1. Signaling pathways activated by MHC/ T cell receptor (TCR) engagement and effect of immune 
checkpoint inhibitors.
(a) Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) exerts negative, inhibitory signals when bind to 
their ligands Programmed Cell Death-Ligand 1, and 1 (PD-L1/PDL-2) on APCs and tumor cells and do not 
attack the tumor. The interaction of TCR with the target antigen presenting cell (APC) (the TCR/MHC complex) 
activates intracellular phosphotyrosine kinases (ZAP-70) that mediate signaling via phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) and various transduction molecules. T cell activation 
is meditated via key co-stimulatory factors, based on interactions of CD28/CTLA-4 or PD-1 on T cells with their 
respective ligands B7-1(CD80)/B7-2 (CD86) or PD-L1/PD-L2 on APCs and tumor cells. CD28, when binding to 
its CD80(B71)/CD86(B7-2) receptor, exerts positive (+) activating signals; in contrast, the CTLA-4 on activated 
T cells binds with higher affinity to CD80/CD86 and exerts negative (–) inhibitory signals, blocking T cell 
activation. This interaction activates sequentially downstream events, leading via the IL-2 promoter and Janus 
kinases to cell proliferation and T cell differentiation. The application of target-specific immunotherapies 
in autoimmune diseases is based on therapeutic monoclonal antibodies or fusion proteins directed against 
the positive activating CD28 and CD80/86 (B7-1,2) signals or in enhancing inhibition, via the CTLA-4 Ig fusion 
protein, like the drug Abatacept,which is effective in rheumatoid arthritis.
(b) Effect of ICPIs: positive co-stimulation and T cell activation. The ICPIs prevent the CTLA-4 or PD-1 from binding 
to their respective receptors CD80/86 and PDL-1 (noted by *) and, by doing so, they inhibit the inherent ‘inhibitory’ 
(–) co-stimulatory interactions between T cells and tumor cells. Such inhibition of inhibitory signals results in 
positive co-stimulation that unleashes a strong and uncontrolled T cell activation ( like ‘taking the brakes off’ 
the immune system). The ICPI-induced activated T cells enhance Th1 and Th-17 cell responses, increase the 
production of cytokines, such as IL-6 and IL-17, leading to abnormal T-regulatory (Treg) cell function and altered 
Treg/Th17 cell axis, which is critical for humoral immunity and development of autoimmune disease.
CTLA-4, cytotoxic T lymphocyte antigen; ICAM, intercellular adhesion molecule; ITAM, immunoreceptor tyrosine-based 
activation motifs; LFA-1, lymphocyte function antigen 1; LFA-3, lymphocyte function antigen 3; NFAT, nuclear factor of 
activated T cells; PLC, phospholipase C; PTK, protein tyrosine kinase; STAT, signal transducer and activator of transcription; 
ZAP-70, zeta-chain associated protein 70.
Therapeutic Advances in Neurological Disorders 11
4 journals.sagepub.com/home/tan
60% response rate was seen using nivolumab and 
ipilimumab for metastatic melanoma, compared 
to an 11% response rate for ipilimumab alone.1
Neurological complications of ICPIs
Incidence and risk factors. Immune-related 
adverse events resulting from enhanced T cell 
activation essentially affect nearly every organ, 
with varying degrees of severity (Table 1), includ-
ing colitis, hepatitis, pneumonitis, hypothyroid-
ism, autoimmune retinopathy, uveitis or iritis and 
rheumatic or musculoskeletal complications. 
They most commonly cause a series of autoim-
mune neurological events affecting muscle, neu-
romuscular junction, nerves, routes, spinal cord 
and brain, as described below. These events vary 
in severity and occur at any point during ICPI 
administration, but 60–80% occur early, within 
the first 4 months of therapy initiation.1–10
The overall incidence of neurological complica-
tions ranges from 2% to 4%.1–9 Mild events 
(grades 1–2) occur in up to 6–12% of patients 
and consist of nonspecific neurological symp-
toms, such as headaches, dizziness, paresthesias 
or small-fiber sensory neuropathies that do not 
overall impact ICPI continuation. More serious 
events (grades 3–4) occur in fewer than 1%, 
ranging from 0.4% to 0.2% with nivolumab and 
pembrolizumab, 0.3–0.8% with ipilimumab and 
2.4–14% with the combination of PD-1 and 
CTLA-4 inhibitors (i.e. ipilimumab with nivolu
mab).1–9,14–16 In one series, among 347 patients 
treated with pembrolizumab or nivolumab, 10 
(2.9%; 7 on pembrolizumab and 3 on nivolumab) 
developed neuromuscular complications after a 
median of 5.5 (range: 1–20) cycles of treatment.6 
ICPIs can also precipitate preexisting autoim-
mune diseases, with an estimated 27–42% risk 
for mild to moderate exacerbations.7,13,17–20 
Ipilimumab seems more commonly associated 
with neurological events, although PD-1 inhibi-
tors may confer a greater risk over time because of 
their prolonged administration.
Neurological events. Inflammatory myopathies. 
Among all the inflammatory myopathy sub-
types,21–23 dermatomyositis, polymyositis and 
especially necrotizing autoimmune myositis 
(NAM) are the most frequent autoimmune myop-
athies triggered, especially by pembrolizumab, ipi-
limumab and nivolumab.6,10,18,20,24–29 NAM, which 
is emerging as the commonest type of inflamma-
tory myopathy,23 is also the most common subtype 
associated with ICPIs. In some patients, NAM 
may coexist with MG, or MG-like symptoms, pre-
senting with head drop, proximal muscle weakness, 
myalgia, dyspnea, ophthalmoparesis or bulbar weak-
ness. Among 654 patients receiving ICPIs (pembro-
lizumab = 389; nivolumab = 264; both = 1), 5 on 
pembrolizumab had biopsy-proven myopathies (2 
Table 1. Common immune complications of ICPIs.
A. Systemic autoimmune complications
1. Colitis;
2. hepatitis;
3. pneumonitis;
4. hypothyroidism;
5. retinopathy, uveitis or iritis;
6. rheumatic or musculoskeletal events.
B. Autoimmune neurological complications
i) Mild events (grades 1–2) with nonspecific neurologic symptoms:
headaches, dizziness, paresthesias or small-fiber sensory neuropathies.
ii) Serious events (grades 3–4), manifested as:
1. inflammatory myopathies;
2. myasthenia gravis;
3. vasculitis;
4. neuropathies;
5. aseptic meningitis;
6. autoimmune encephalitis;
7. multiple sclerosis;
8. hypophysitis.
iii) Trigger of preexisting autoimmune neurological diseases
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NAM, 1 dermatomyositis, and 2 nonspecific myop-
athy).6 Eosinophilic fasciitis28 and orbital myosi-
tis30 have been also reported.
ICPIs can also exacerbate polymyositis.29 In one 
such patient who was stable on IVIg, CK increased 
within 1 week after starting pembrolizumab, with 
worsening of painful weakness and further CK 
elevation after subsequent infusions. Of interest, 
myositis improved after 10 months of therapy 
while the patient became tumor-free.
Myasthenia gravis. A number of patients 
develop ocular MG 7–11 weeks after ICPI initia-
tion, most often using pembrolizumab and 
nivolumab;31–34 others develop generalized MG, 
including myasthenic crisis. A common coinci-
dence is the elevated CK,34 as mentioned earlier. 
ICPIs can also exacerbate preexisting MG.29,32 In 
one study, the incidence of MG was 0.12%, 
occurring in 12 patients among 9869 treated with 
nivolumab.34 MG can evolve rapidly at all stages 
of these treatments, even after completion, and 
generally responds well to corticosteroids, IVIg or 
plasmapheresis.
Vasculitis. Vasculitis occurs either in single organs 
(retina and uterus), or in the form of giant cell arte-
ritis10,20,24 and polymyalgia rheumatica, as reported 
in two patients treated with ipilimumab.10
Neuropathies. Neuropathies occur in fewer 
than 1% and vary in severity from the small-fiber 
sensory type (as commonly seen with chemo-
therapies, not affecting the continuation of 
ICPIs), to more typical immune-mediated, such 
as Guillain–Barré syndrome (occurring in 0.1–
0.2%) and chronic inflammatory demyelinating 
polyneuropathy (CIDP).2–4,10–13,15,35–39 Because 
melanocyte antigens, such as GM2, GM3, GD2, 
and GD3 are present in both, the gangliosides 
on the myelin sheath and the melanomas,40 
molecular mimicry and ICPI-induced disruption 
of immune homeostasis might explain the devel-
opment of CIDP.4,24,35 Polyradiculoneuropathies, 
meningoradiculoneuritis with facial diplegia, 
muscle weakness and uptake of the caudal nerve 
fibers have been reported, responding rapidly to 
high-dose steroids or IVIg.4,24,35,38 Cranial mon-
oneuropathies affecting the optic nerve, abdu-
cens or facial nerves, either isolated or in a 
setting of meningoradiculoneuritis, can also 
occur3,16,41
Aseptic meningitis. Aseptic meningitis typically 
presents at 1–7 weeks after the first dose of 
ICPIs and occurs in approximately 0.1–0.2% of 
patients.3,16,20,42 Cerebrospinal fluid (CSF) shows 
lymphocytosis and magnetic resonance imaging 
(MRI) may show meningeal enhancement.42 Most 
patients respond to steroids.3,36
Autoimmune encephalitis. Autoimmune 
encephalitis occurs in 0.1–0.2% of patients within 
days or a few weeks after ICPI initiation, espe-
cially with combined treatment of ipilimumab 
and nivolumab.4,12–16,39,42 A number of patients 
have NMDA receptor (NDMAR) antibodies, as 
seen in other autoimmune encephalopathies, or 
combined with paraneoplastic antibodies such as 
contactin-associated protein-like 2 or anti-Hu.15 
Because NMDAR is expressed on melanocytes 
and the GRIN2A gene that encodes the NMDAR 
subunit GluN2A is highly mutated in patients 
with melanomas,29,43 the encephalitis probably 
represents molecular mimicry when the ICPI-
induced disruption of immune tolerance triggers 
antibodies against the NMDAR expressed on 
both melanoma cells and the central nervous 
system (CNS) synapses.4,13,29,43 Autoimmune 
encephalitis responds to high-dose steroids or 
standard immunotherapies.4,13 One case with 
anti-Hu antibodies responded to natalizumab, 
suggesting a role of hyperactive T cells.44 Because 
natalizumab decreases CNS inflammation with-
out compromising the immune reaction against 
systemic cancer localizations, it was suggested 
that natalizumab could be a more suitable ther-
apy if continuation of ICPIs is indicated.44
Multiple sclerosis. Exacerbation of MS or de 
novo occurrence of CNS demyelinating disease, 
such as optic neuritis, transverse myelitis and 
acute tumefactive demyelinating lesions, can 
occur within weeks or months after treatment 
with ipilimumab, pembrolizumab or 
nivolumab.13,45–47 Transition from radiologically 
isolated syndrome to clinically definite multiple 
sclerosis after ipilimumab initiation was also 
reported.13 One MS patient after two courses of 
ipilimumab, given 2 years apart, had complete 
melanoma regression but developed a transient 
but massive increase in clinical or MRI activity 
after each ipilimumab course. In this patient, 
investigation of TCR gene sequencing revealed 
two distinct oligoclonal CD4 and CD8 T cell rep-
ertoires induced by the anti-CTLA-4 effect of 
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ICPIs; an immune response against the tumor 
and another against CNS antigens resulted in 
profound MS disease activity.13,48 Because this 
patient subsequently remained stable with IFNβ, 
it was suggested that subclinical or even clinical 
CNS inflammation may not be a strict contrain-
dication to using ICPIs.13,48 An enhanced in situ 
CNS inflammation may explain the MS relapses 
because under inflammatory conditions PDL1 is 
highly expressed on astrocytes and microglia; 
blocking the interaction between PDL1 and PD1 
on lymphocytes infiltrating the CNS might there-
fore increase the local inflammatory response.13
Hypophysitis. Hypophysitis may occur in up to 
5–10% of patients, usually 6–12 weeks after ICPI 
initiation, representing an immune-related toxic-
ity. It presents with headache, fatigue, dizziness 
and multiple anterior pituitary hormone deficien-
cies (mostly adrenocorticotropic and thyroid-
stimulating hormone).4,13 Serum level of pituitary 
hormones is low and brain MRI may show 
enhancement and swelling of the pituitary gland.3 
Hypophysitis responds to high-dose steroids 
along with hormonal supplementation.49
Therapies. Immunotherapies are generally 
guided by the type and severity of the neurologi-
cal event, the relative risks and benefit of treat-
ment, and any associated comorbidities or 
potential contraindications. There is no optimal 
or standardized therapeutic regimen and treat-
ments remain still empirical, based on our exist-
ing experience with each of these disorders in 
non-cancer patients. Intravenous corticosteroids, 
IVIg and plasmapheresis are the first-line thera-
pies, followed by immunosuppressants, such as 
mycofenolate, rituximab, methotrexate and cyclo-
phosphamide. Alternative immunosuppressive 
agents not commonly used in neurologic condi-
tions have been considered in refractory cases 
including proteasome inhibitors (bortezomib), 
tacrolimus or IL-17 blockers.7
Many oncologists in a setting of a potentially 
treatable immune-related neurological complica-
tion recommend continuation of ICPIs until the 
underlying malignancy is halted; others prefer to 
discontinue ICPIs if complete response has been 
achieved; and still others believe that if a durable 
response was observed with only a few doses, the 
duration of ICPIs can be shortened once the 
immune system is appropriately primed. In gen-
eral, in severe cases ICPI therapies are stopped 
until the neurological event is controlled with 
prompt immunotherapy; reinstitution of ICPIs 
remains at the physician’s discretion, considering 
life expectancy and cancer severity.15,20
Based on anecdotal data, there has been a sugges-
tion that the development of neurological events 
may be associated with an increase in tumor 
objective response rate (ORR).15,20,24 ORR was 
reported in 50–70% of patients who developed 
neurological events, compared to 20–30% who 
did not, with an increased overall survival.15,20,24 
The significance of these small and uncontrolled 
but interesting observations is still unclear. Based 
on the available limited data, however, the immu-
notherapies applied to treat the neurological com-
plications do not seem to attenuate the efficacy of 
ICPIs.
Unresolved issues. As the use of ICPIs grows rap-
idly, it is likely that the incidence of neurological 
events will increase. It is hoped that the growing 
experience will clarify the following issues and 
questions that remain still unsettled.1
Preexisting autoimmune disease and ICPI 
treatment. In patients with known but inactive 
autoimmune disorders, ICPIs, by disturbing 
immune tolerance, can unravel preexisting auto-
immunity leading to disease exacerbations in 27–
38% of patients. A classic example is the severe 
exacerbation of MS during ipilimumab therapy, 
even though the oncological response was good.45 
As many of the neurological events can be suc-
cessfully managed, the risk–benefit ratio seems to 
favor using the life-saving ICPIs in patients with 
subclinical CNS inflammatory disease.19 Until 
predicting factors are identified, however, and the 
practical risk–benefit ratio is defined, the use of 
ICPIs in such settings must be individualized, 
especially since some of the neurological compli-
cations can be severe and life-threatening.
The paraneoplastic component as a contrib-
uting substrate. ICPIs could theoretically 
promote immune-mediated paraneoplastic neu-
rological syndromes, especially when these con-
ditions result from a cross-reactive immune 
response against a self-antigen expressed on both 
neural cells and tumor cells.13 In a phase II trial, 
antineuronal antibodies such as anti-Hu, and 
anti-Yo (implicated in paraneoplastic cerebellar 
degeneration and subacute sensory neuropathy) 
were detectable in 45% of patients with small cell 
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lung cancer treated with ipilimumab and chemo-
therapy. Although at times difficult, clinicians 
must be cognizant in distinguishing whether a 
neurological event is part of the paraneoplastic 
process or an ICPI-triggered autoimmune dis-
ease. Paraneoplastic complications evolve slowly 
and do not fit the autoimmune and temporal 
profile of the ICPI-triggered disorders; in con-
trast, the autoimmune diseases evolve rapidly 
and occur at all stages of ICPI treatments, even 
after completion.13
Susceptibility to ICPI-induced autoimmune 
disease. It remains unclear why autoimmune 
disorders occur in some patients without preexist-
ing autoimmunity but not in others, even though 
the T cell activation is always profound. Whether 
polymorphisms in CTLA-4 play a role, as sug-
gested,4,50 remains to be explored. Screening for 
common autoantibodies before ICPI initiation 
may provide some clues, but several of these anti-
bodies are non-pathogenic or very specific and it 
remains uncertain whether they can predict sus-
ceptibility. In a retrospective literature review of 
123 patients in 43 different publications with 
obvious limitations, 75% of patients receiving 
ICPIs had an exacerbation of preexisting autoim-
mune disease or immune-related adverse events 
of varying severity; of interest, patients receiving 
immunosuppressive therapy at initiation of ICPIs 
seemed to have fewer adverse events.51 The prac-
ticality of this observation remains uncertain, 
given the significant study limitations.
Conventional immunotherapies in conjunc-
tion with ICPIs. It has been questioned whether 
the immunosuppressants used to treat the ICPI-
triggered neurological events can reduce the 
ICPIs’ antitumor efficacy and whether they 
increase the risk for opportunistic infections. The 
latter is of concern because in a setting of cancer 
and prior ICPI administration, the risk of infec-
tions, especially progressive multifocal leukoen-
cephalopathy (PML), may be high, necessitating 
vigilance and close follow up.
Restarting ICPI treatment after a major 
immune event. The safety of retreatment with 
ICPI remains unsettled. Although this decision 
depends on several factors, especially life expec-
tancy, the severity of the initial immune-related 
neurological event undoubtedly plays a funda-
mental role. Using a different ICPI may be an 
evolving option because immune-related adverse 
events associated with one class of ICPIs (e.g. 
anti-CTLA-4) may not necessarily recur with 
another class (e.g. anti-PD-1). More data are 
clearly needed.
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